22:15 , Aug 2, 2018 |  BC Innovations  |  Tools & Techniques

Model firsts

By combining disparate data into coherent mechanistic models, quantitative systems pharmacology is becoming a key tool for picking the right dose for first-in-human trials and other early make-or-break decisions. Advocates see it as part of...
00:34 , Jun 9, 2017 |  BC Extra  |  Clinical News

Team describes off-target effects of Bial's FAAH inhibitor

In a paper published in Science , researchers characterized off-target activities of fatty acid amide hydrolase (FAAH) inhibitor BIA 10-2474 that they say may have played a role in the compound’s clinical neurotoxicity that led...
20:36 , Apr 13, 2017 |  BC Innovations  |  Targets & Mechanisms

Allosteric en-ABL-ement

Novartis AG has developed a new strategy to prevent leukemias from becoming resistant to its CML drugs against BCR-ABL . Rather than combining the inhibitors with other classes of cancer therapies, the company is doubling...
08:00 , Nov 6, 2014 |  BC Innovations  |  Targets & Mechanisms

Greasing insulin

An entirely new class of fatty acids has just been discovered that potentially is more potent than the w-3 fatty acids found in fish oil. The new fatty acids-which work through G protein-coupled receptor 120,...
07:00 , Jun 9, 2014 |  BC Week In Review  |  Clinical News

Iclusig ponatinib: Preliminary Phase III data

Preliminary data from the discontinued confirmatory Phase III EPIC trial in 307 newly diagnosed leukemia patients showed that a higher proportion of patients receiving Iclusig achieved <10% BCR-ABL transcript level at 3 months vs. imatinib...
07:00 , Jun 10, 2013 |  BC Week In Review  |  Company News

AbbVie sales and marketing update

AbbVie said FDA approved a 36,000 lipase-unit dose of Creon pancrelipase delayed-release capsules to treat pancreatic exocrine insufficiency (PEI). The product comprises a combination of porcine-derived lipases, proteases and amylases. The wholesale acquisition cost of...
08:00 , Dec 6, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Hyperlipidemia Angiopoietin-like 8 (ANGPTL8); ANGPTL3 In vitro and mouse studies suggest inhibiting activation of ANGPTL8 or ANGPTL3 could help treat hyperlipidemia. Cleavage of ANGPTL3...
08:00 , Nov 12, 2012 |  BioCentury  |  Product Development

Omega-3 for all

Omthera Pharmaceuticals Inc. thinks Phase III data for Epanova show the omega-3 fatty acid could compete with approved lipid-lowering drugs Lovaza and Vascepa icosapent ethyl in patients who are already taking statins to reduce the...
08:00 , Feb 27, 2012 |  BC Week In Review  |  Clinical News

Xenical orlistat regulatory update

EMA's CHMP concluded that the benefits of orlistat-containing medicines for obesity outweigh the potential risks of severe liver injuries. The committee found no strong evidence that orlistat increased the risk of severe liver injury. CHMP...
07:00 , Oct 3, 2011 |  BC Week In Review  |  Clinical News

Xenical orlistat regulatory update

EMA began a review of serious liver injuries reported in patients receiving medicines containing orlistat for obesity. The agency said it identified 21 suspected cases of hepatic events, of which 4 were cases of severe...